Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Satellos Bioscience Inc. reported significant progress in 2025, including closing a $57.2 million equity financing, commencing Nasdaq trading under ticker MSLE, and initiating two Phase 2 clinical trials (BASECAMP and TRAILHEAD) for its lead candidate SAT-3247 targeting Duchenne muscular dystrophy (DMD). Clinical data showed maintained or improved …